# NRG-HN004 (NCT03258554)

> Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: locoregionally advanced head and neck cancer, cisplatin contraindication

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03258554
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma of Unknown Primary; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions: Cetuximab; Durvalumab; Intensity-Modulated Radiation Therapy; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 196
- Primary outcome: Number of Participants With Dose-limiting Toxicity (DLT) [Lead-in Phase]
- Primary outcome: Progression-free Survival (Percentage of Participants Alive Without Progression) [Phase II Primary]
- Primary outcome: Overall Survival (Percentage of Participants Alive) [Originally Phase III Primary / Now Phase II Secondary]

## Indexed commentary on NRG-HN004 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nrg-hn004-nct03258554

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03258554", "email": "<work email>"}; the inbox owner confirms by the emailed link.